Prof John Hopper, Director (Research) of the Centre for Epidemiology and Biostatistics stated that; "This Research Agreement provides us with the basis to translate our scientific work into the clinical arena. Risk stratification of patients to improve breast cancer screening and prevention has significant potential upside benefit for both women and the health system."Genetic Technologies' Scientific Director, Richard Allman commented; "I am extremely pleased with the execution of this agreement as we seek to enhance our portfolio of proprietary risk assessment products. In addition to our colorectal cancer test under development, this represents the Company's continued commitment to the development of SNP based genetic resources." Preliminary data from the study is expected to be available in the second quarter of 2018. FOR FURTHER INFORMATION PLEASE CONTACT Dr Paul Kasian Director & Interim CEO Genetic Technologies Limited + 61 3 8412 7000 Jason Wong (USA)Blueprint Life Science Group+1 (415) 375 3340, Ext. 4 About The University of Melbourne Founded in 1853, The University of Melbourne is an internationally recognised, research-intensive university with a strong tradition of excellence in teaching, research and community engagement spanning more than 160 years. Its outstanding performance in international rankings puts The University of Melbourne at the forefront of higher education globally. It is ranked number 1 in Australia by the Times Higher Education World University Rankings and 32nd worldwide. Melbourne's position as Australia's top University has also been reaffirmed in the 2017 Shanghai Jiao Tong rankings, in which it has moved up to 39th in the World. The University is uniquely located on the fringe of the city of Melbourne's central business district. It serves as a hub for the Parkville research precinct - one of the world's leading centres of medical and biotechnological research. About 50,000 of the best and brightest students from around the globe come to study at the University of Melbourne.
About Genetic Technologies LimitedGenetic Technologies is a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company's lead product, BREVAGen plus ®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. For more information, please visit www.brevagenplus.com and www.phenogensciences.com. Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please visit www.gtgcorporate.com Safe Harbor Statement Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act . The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.